Na Eun Lee | Extracellular Vesicles | Best Researcher Award

Ms. Na Eun Lee | Extracellular Vesicles | Best Researcher Award

Senior Research Scientist | Sungkyunkwan University | South Korea

Ms. Na Eun Lee, Ph.D. Candidate at the Department of Health Sciences and Technology (SAIHST), Sungkyunkwan University, is an accomplished researcher specializing in regenerative medicine, stem cell biology, and translational health sciences. She holds a Master’s degree in Health Sciences and Technology from Sungkyunkwan University and a Bachelor’s degree in Applied Biochemistry from Konkuk University. Currently pursuing her doctoral studies, she integrates molecular and cellular approaches to advance extracellular vesicle-based therapeutics and skin rejuvenation technologies. Throughout her professional career, Ms. Lee has held senior scientific and leadership positions at prominent biomedical companies and research institutions, where she directed projects in cell therapy development, angiogenesis research, and clinical translation. Her scholarly contributions include publications in high-impact journals such as Cytotherapy, Biochemical and Biophysical Research Communications, and the International Journal of Molecular Sciences, highlighting innovations in mesenchymal stromal cell biology and nano-encapsulation delivery systems. Renowned for her expertise in extracellular vesicle analysis, molecular diagnostics, and regenerative research, Ms. Lee’s work bridges fundamental science and clinical application. She has been recognized for her research excellence and leadership in biomedical innovation, contributing actively to the advancement of stem cell-based therapeutic strategies and representing a distinguished example of scientific dedication and translational impact in the field of health sciences and technology.

Profiles: ORCID

Featured Publications

1 S. J. Yang, J. K. Son, S. J. Hong, N. E. Lee, D. Y. Shin, S. H. Park, S. B. An, Y. C. Sung, J. B. Park, and H. M. Yang, et al., “Ectopic vascularized bone formation by human umbilical cord-derived mesenchymal stromal cells expressing bone morphogenetic factor-2 and endothelial cells,” Biochemical and Biophysical Research Communications.

2 N. E. Lee, S. J. Kim, S. J. Yang, S. Y. Joo, H. Park, K. W. Lee, H. M. Yang, and J. B. Park, “Comparative characterization of mesenchymal stromal cells from multiple abdominal adipose tissues and enrichment of angiogenic ability via CD146 molecule,” Cytotherapy.

3 H. M. Yang, H. J. Choi, D. P. Hong, S. Y. Joo, N. E. Lee, J. Y. Song, Y. L. Choi, J. Lee, D. Choi, B. Kim, et al., “The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex,” Experimental and Molecular Pathology.

Lixin Yan | Pharmacology | Best Researcher Award

Mrs. Lixin Yan | Pharmacology | Best Researcher Award

Medical manager | Sinocelltech Ltd | China

Mrs. Lixin Yan is an accomplished medical manager with extensive experience in clinical research, specializing in oncology, infectious diseases, vaccines, and metabolic products. Over the years, she has led multiple Phase I–III clinical trials, contributing to protocol development, medical monitoring, feasibility assessment, and regulatory submissions. Her work has been instrumental in the clinical development of innovative therapies, including PD-1 inhibitors, EGFR-targeted treatments, HPV and COVID-19 vaccines, insulin, and GLP-1 products. She demonstrates strong expertise in GCP compliance, regulatory processes, and cross-functional team collaboration, ensuring high-quality research outcomes. Mrs. Yan has published impactful peer-reviewed articles, including first-author papers, highlighting her ability to generate reliable clinical evidence. Her dedication to advancing medical science through rigorous research and mentorship reflects her potential to lead future high-impact studies. Her measurable research impact is demonstrated through 68 citations, 5 documents, and an h-index of 4 according to Scopus.

Profile: Scopus

Featured Publications

1. L. Yan, J. Yi, D. Liu, J. Li, A. A. H. Baidoo, and L. Xie, “Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial,” Contemporary Clinical Trials Communications, 2025.